<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medgen</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская генетика</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Genetics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-7998</issn><publisher><publisher-name>Publishing House «Genius Media» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25557/2073-7998.2025.01.46-50</article-id><article-id custom-type="elpub" pub-id-type="custom">medgen-2603</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Ассоциация полиморфизмов генов микроРНК MIR146A (rs2910164), MIR758 (rs1885068), MIR33a (rs9620000) с меланомой</article-title><trans-title-group xml:lang="en"><trans-title>Association of polymorphisms of microRNA genes MIR146A (rs2910164), MIR758 (rs1885068), MIR33a (rs9620000) with melanoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стефанова</surname><given-names>Ю. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Stefanova</surname><given-names>Yu. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>350063, г. Краснодар, ул. имени Митрофана Седина, д. 4</p></bio><bio xml:lang="en"><p>4, Mitrofana Sedina st., Krasnodar, 350063</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Порханова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Porkhanova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>350063, г. Краснодар, ул. имени Митрофана Седина, д. 4</p></bio><bio xml:lang="en"><p>4, Mitrofana Sedina st., Krasnodar, 350063</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мурашко</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Murashko</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>350063, г. Краснодар, ул. имени Митрофана Седина, д. 4</p></bio><bio xml:lang="en"><p>4, Mitrofana Sedina st., Krasnodar, 350063</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тимошкина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Timoshkina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>344037, г. Ростов-на-Дону, 14-я линия, 63</p></bio><bio xml:lang="en"><p>63, 14th line, Rostov-on-Don, 344037</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимов</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimov</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>344037, г. Ростов-на-Дону, 14-я линия, 63</p></bio><bio xml:lang="en"><p>63, 14th line, Rostov-on-Don, 344037</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тимофеева</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Timofeeva</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>344037, г. Ростов-на-Дону, 14-я линия, 63</p></bio><bio xml:lang="en"><p>63, 14th line, Rostov-on-Don, 344037</p></bio><email xlink:type="simple">timofeeva.sophia@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Кубанский государственный медицинский университет Министерства здравоохранения России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuban State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр онкологии Министерства здравоохранения России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>03</month><year>2025</year></pub-date><volume>24</volume><issue>1</issue><fpage>46</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Стефанова Ю.Ю., Порханова Н.В., Мурашко Р.А., Тимошкина Н.В., Максимов А.Ю., Тимофеева С.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Стефанова Ю.Ю., Порханова Н.В., Мурашко Р.А., Тимошкина Н.В., Максимов А.Ю., Тимофеева С.В.</copyright-holder><copyright-holder xml:lang="en">Stefanova Y.Y., Porkhanova N.V., Murashko R.A., Timoshkina N.V., Maksimov A.Y., Timofeeva S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medgen-journal.ru/jour/article/view/2603">https://www.medgen-journal.ru/jour/article/view/2603</self-uri><abstract><sec><title>Введение</title><p>Введение. Накопленные данные показывают, что микроРНК играют решающую роль практически во всех биологических и патофизиологических процессах, таких как дифференцировка клеток, регуляция клеточного цикла, липидный обмен, воспаление, неврологические, сердечно-сосудистые и метаболические расстройства и рак, включая меланому.</p></sec><sec><title>Цель</title><p>Цель: поиск ассоциации между полиморфными вариантами MIR146A (rs2910164), MIR758 (rs1885068), MIR33a (rs9620000) и риском развития меланомы.</p></sec><sec><title>Методы</title><p>Методы. В качестве материала для исследования использовали парафиновые блоки (FFPE) 82 лиц с меланомой и периферическую кровь 35 доноров контрольной группы. ДНК выделяли из срезов FFPE с помощью коммерческого набора QIAamp DNA FFPE Tissue Kit (QIAGENE, Германия). Праймеры для ПЦР подбирали с помощью программы WASP. Геномную ДНК выделяли набором QIAamp DNA Blood mini kit (Qiagen, Germany). Генотипирование проводили методом аллель-специфичной ПЦР смесью qPCRmix –HS («Евроген» России) на приборе Real-time CFX96 Touch (США). Анализ равновесия Харди-Вайнберга и различия в распределении вариантов аллелей между группами пациентов и контроля оценивали с помощью критерия χ2. Для оценки риска развития меланомы использовали коэффициенты отношения шансов (ОШ).</p></sec><sec><title>Результаты</title><p>Результаты. Установлено, что аллель A гена MIR146A (rs2910164) (ОШ = 2,24, 95% ДИ = 1,24–4,03; p=0,02) и генотип ТТ гена MIR33a (rs9620000) (ОШ = 2,98, 95% ДИ = 1,17–7,60; p=0,03) ассоциированы с повышенным риском развития меланомы. Наличие полиморфного аллеля гена MIR758 (rs1885068) не ассоциировано развитием меланомы.</p></sec><sec><title>Заключение</title><p>Заключение. Таким образом, результаты исследования подчёркивают важность поиска диагностических биомаркеров в некодирующей области генома.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Accumulated data show that microRNA plays a crucial role in almost all biological and pathophysiological processes, such as cell cycle regulation, cell differentiation, lipid metabolism, neurological, cardiovascular and metabolic diseases and cancer, including melanoma.</p></sec><sec><title>Aim</title><p>Aim: to search for associations between polymorphic variants MIR146A (rs2910164), MIR758 (rs1885068), MIR33a (rs9620000) and the risk of melanoma.</p></sec><sec><title>Methods</title><p>Methods. Paraffin blocks of 82 people with melanoma and peripheral blood of 35 donors of the control group were used as the material for the study. DNA was used from paraffin block sections (FFPE) using a commercial QIAamp DNA FFPE Tissue Kit (QIAGENE, Germany). Primers for PCR were selected using the WASP program. Genomic DNA is popular with the QIAamp DNA Blood mini kit (Qiagen, Germany). Genotyping of animals using the allele-specific PCR mixture qPCRmix –HS (Eurogen, Russia) on the Real-time CFX96 Touch (USA). Analyze the Hardy-Weinberg equilibrium and differences in the distributed alleys of variants between experimental patients and control measurements using the χ2 criterion. To assess the risk of developing melanoma, we used odds ratios (OR).</p></sec><sec><title>Results</title><p>Results. The study found that the allele A of the MIR146A gene (rs2910164) (OR = 2.24, 95% CI = 1.24–4.03; p = 0.02) and the TT genotype of the MIR33a gene (rs9620000) (OR = 2.98, 95% CI = 1.17–7.60); p = 0.03) are associated with an increased risk of melanoma. The presence of a polymorphic allele of the MIR758 gene (rs1885068) is not associated with the development of melanoma.</p></sec><sec><title>Conclusion</title><p>Conclusion. Thus, the results of the study emphasize the depth of the search for diagnostic biomarkers in the non-coding region of the genome.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>меланома кожи</kwd><kwd>микроРНК</kwd><kwd>MIR146A</kwd><kwd>MIR758</kwd><kwd>MIR33a</kwd></kwd-group><kwd-group xml:lang="en"><kwd>melanoma</kwd><kwd>microRNA</kwd><kwd>MIR146A</kwd><kwd>MIR758</kwd><kwd>MIR33a</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Thyagarajan A., Shaban A., Sahu R. P. MicroRNA-directed cancer therapies: implications in melanoma intervention. Journal of Pharmacology and Experimental Therapeutics. 2018;364(1):1-12. doi:10.1124/jpet.117.242636</mixed-citation><mixed-citation xml:lang="en">Thyagarajan A., Shaban A., Sahu R. P. MicroRNA-directed cancer therapies: implications in melanoma intervention. Journal of Pharmacology and Experimental Therapeutics. 2018;364(1):1-12. doi:10.1124/jpet.117.242636</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lages E. et al. MicroRNAs: molecular features and role in cancer. Frontiers in bioscience. 2012;17:2508. doi:10.2741/4068</mixed-citation><mixed-citation xml:lang="en">Lages E. et al. MicroRNAs: molecular features and role in cancer. Frontiers in bioscience. 2012;17:2508. doi:10.2741/4068</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Streicher K. L. et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 2012; 31(12): 1558-1570. doi:10.1038/onc.2011.345</mixed-citation><mixed-citation xml:lang="en">Streicher K. L. et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 2012; 31(12): 1558-1570. doi:10.1038/onc.2011.345</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Brennecke J. et al. Principles of microRNA–target recognition. PLoS biology. 2005; 3(3): e85. doi:10.1371/journal.pbio.0030085</mixed-citation><mixed-citation xml:lang="en">Brennecke J. et al. Principles of microRNA–target recognition. PLoS biology. 2005; 3(3): e85. doi:10.1371/journal.pbio.0030085</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schadendorf D., Fisher DE., Garbe C., et al. Melanoma. Nature reviews. Disease primers. 2015;1:15003. https://doi.org/10.1038/nrdp.2015.3</mixed-citation><mixed-citation xml:lang="en">Schadendorf D., Fisher DE., Garbe C., et al. Melanoma. Nature reviews. Disease primers. 2015;1:15003. https://doi.org/10.1038/nrdp.2015.3</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Delyon J., Lebbe C., Dumaz, N. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. Current opinion in oncology, 2020;32(2):79–84. https://doi.org/10.1097/CCO.0000000000000606</mixed-citation><mixed-citation xml:lang="en">Delyon J., Lebbe C., Dumaz, N. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. Current opinion in oncology, 2020;32(2):79–84. https://doi.org/10.1097/CCO.0000000000000606</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Murphy B.M., Terrell E.M., Chirasani V.R., et al. Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation. Nature communications, 2022:13(1):3153. https://doi.org/10.1038/s41467-022-30881-9</mixed-citation><mixed-citation xml:lang="en">Murphy B.M., Terrell E.M., Chirasani V.R., et al. Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation. Nature communications, 2022:13(1):3153. https://doi.org/10.1038/s41467-022-30881-9</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Heppt M.V., Siepmann T., Engel J., et al. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC cancer, 2017;17(1):536. https://doi.org/10.1186/s12885-017-3529-5</mixed-citation><mixed-citation xml:lang="en">Heppt M.V., Siepmann T., Engel J., et al. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC cancer, 2017;17(1):536. https://doi.org/10.1186/s12885-017-3529-5</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage. Nature reviews Molecular cell biology, 2004;5(11):875-885.</mixed-citation><mixed-citation xml:lang="en">Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage. Nature reviews Molecular cell biology, 2004;5(11):875-885.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mandala M., Voit C. Targeting BRAF in melanoma: biological and clinical challenges. Critical reviews in oncology/hematology. 2013;87(3):239–255. https://doi.org/10.1016/j.critrevonc.2013.01.003</mixed-citation><mixed-citation xml:lang="en">Mandala M., Voit C. Targeting BRAF in melanoma: biological and clinical challenges. Critical reviews in oncology/hematology. 2013;87(3):239–255. https://doi.org/10.1016/j.critrevonc.2013.01.003</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jakob J.A., Bassett R.L.Jr., Ng C.S., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014–4023. https://doi.org/10.1002/cncr.26724</mixed-citation><mixed-citation xml:lang="en">Jakob J.A., Bassett R.L.Jr., Ng C.S., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014–4023. https://doi.org/10.1002/cncr.26724</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ugurel S., Thirumaran R.K., Bloethner S., et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PloS one. 2007;2(2):e236. https://doi.org/10.1371/journal.pone.0000236</mixed-citation><mixed-citation xml:lang="en">Ugurel S., Thirumaran R.K., Bloethner S., et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PloS one. 2007;2(2):e236. https://doi.org/10.1371/journal.pone.0000236</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Devitt B., Liu W., Salemi R., et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment cell &amp; melanoma research. 2011;24(4):666–672. https://doi.org/10.1111/j.1755-148X.2011.00873.x</mixed-citation><mixed-citation xml:lang="en">Devitt B., Liu W., Salemi R., et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment cell &amp; melanoma research. 2011;24(4):666–672. https://doi.org/10.1111/j.1755-148X.2011.00873.x</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang S., Xie R., Zhong A., et al. Targeted therapeutic strategies for melanoma. Chin Med J (Engl). 2023;136(24):2923-2930. doi: 10.1097/CM9.0000000000002692</mixed-citation><mixed-citation xml:lang="en">Zhang S., Xie R., Zhong A., et al. Targeted therapeutic strategies for melanoma. Chin Med J (Engl). 2023;136(24):2923-2930. doi: 10.1097/CM9.0000000000002692</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bauer J., Buttner P., Murali R., et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011;24(2):345-351. doi:10.1111/j.1755-148X.2011.00837.x</mixed-citation><mixed-citation xml:lang="en">Bauer J., Buttner P., Murali R., et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011;24(2):345-351. doi:10.1111/j.1755-148X.2011.00837.x</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Farzan S.F., Karagas M.R., Christensen B.C., Li Z., Kuriger J.K., Nelson H.H.; New Hampshire Skin Cancer Study. RNASEL and MIR146A SNP-SNP interaction as a susceptibility factor for non-melanoma skin cancer. PLoS One. 2014;9(4):e93602. doi: 10.1371/journal.pone.0093602.</mixed-citation><mixed-citation xml:lang="en">Farzan S.F., Karagas M.R., Christensen B.C., Li Z., Kuriger J.K., Nelson H.H.; New Hampshire Skin Cancer Study. RNASEL and MIR146A SNP-SNP interaction as a susceptibility factor for non-melanoma skin cancer. PLoS One. 2014;9(4):e93602. doi: 10.1371/journal.pone.0093602.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X., Song X., Li H. Transcription elongation factor A-like 7, regulated by miR-758-3p inhibits the progression of melanoma through decreasing the expression levels of c-Myc and AKT1. Cancer Cell Int. 2021;21(1):43. doi: 10.1186/s12935-020-01737-3.</mixed-citation><mixed-citation xml:lang="en">Liu X., Song X., Li H. Transcription elongation factor A-like 7, regulated by miR-758-3p inhibits the progression of melanoma through decreasing the expression levels of c-Myc and AKT1. Cancer Cell Int. 2021;21(1):43. doi: 10.1186/s12935-020-01737-3.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
